The primary tumor location was
an independent prognostic marker in patients with RAS wild - type metastatic colorectal cancer after adjusting for age, gender, synchronous / metachronous disease, consensus molecular subtype, and microsatellite instability and molecular status, according to the results of an analysis (abstract 3503) of data from CALGB / SWOG 80405 presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.
Known and novel
independent prognostic markers were identified in our cohort of proteasome inhibitor and IMiD - treated patients with long follow - up, including events with context - specific prognostic value, such as deletions of the PRDM1 gene.